Scholarlink

Background <p>Neuroblastoma, a neuroendocrine tumor of the sympathetic ganglia, is the leading solid extracranial malignancy in children. The <i>lnc-AMFR-1:1</i> rs4784659 polymorphism in long noncoding RNA (lncRNA) has been reported to be associated with susceptibility to several cancers, but its role in neuroblastoma remains unclear.</p> Methods <p>We studied 402 patients with neuroblastoma and 473 cancer-free controls from Jiangsu Province to assess the association between <i>lnc-AMFR-1:1</i> rs4784659 C &gt; T and neuroblastoma susceptibility using odds ratios (ORs) and 95% confidence intervals (CIs).</p> Results <p>Analysis under any of the genetic models tested failed to reveal a significant link between the rs4784659 C &gt; T polymorphism and neuroblastoma risk (CT vs. CC: adjusted OR = 0.96, 95% CI = 0.73–1.28, <i>P</i> = 0.799; TT vs. CC: adjusted OR = 1.40, 95% CI = 0.77–2.53, <i>P</i> = 0.273; TT/CT vs. CC: adjusted OR = 1.01, 95% CI = 0.77–1.33, <i>P</i> = 0.924; TT vs. CC/CT: adjusted OR = 1.41, 95% CI = 0.79–2.54, <i>P</i> = 0.245). Moreover, stratified analysis revealed no significant associations.</p> Conclusion <p>This study provided no evidence of an association between the <i>lnc-AMFR-1:1</i> rs4784659 C &gt; T polymorphism and the risk of neuroblastoma. These findings warrant validation in larger and more diverse populations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic association analysis of lnc-AMFR-1:1 rs4784659 C > T and neuroblastoma susceptibility in Chinese pediatric patients

  • 期刊论文

  • 发表日期：

    2026年4月15日

查看全文
  • Tianli Feng,
  • Yuling Su,
  • Chunlei Zhou,
  • Xinxin Zhang,
  • Jiabin Liu,
  • Wenli Zhang,
  • Jing He,
  • Xinjiang Huang

摘要

Background

Neuroblastoma, a neuroendocrine tumor of the sympathetic ganglia, is the leading solid extracranial malignancy in children. The lnc-AMFR-1:1 rs4784659 polymorphism in long noncoding RNA (lncRNA) has been reported to be associated with susceptibility to several cancers, but its role in neuroblastoma remains unclear.

Methods

We studied 402 patients with neuroblastoma and 473 cancer-free controls from Jiangsu Province to assess the association between lnc-AMFR-1:1 rs4784659 C > T and neuroblastoma susceptibility using odds ratios (ORs) and 95% confidence intervals (CIs).

Results

Analysis under any of the genetic models tested failed to reveal a significant link between the rs4784659 C > T polymorphism and neuroblastoma risk (CT vs. CC: adjusted OR = 0.96, 95% CI = 0.73–1.28, P = 0.799; TT vs. CC: adjusted OR = 1.40, 95% CI = 0.77–2.53, P = 0.273; TT/CT vs. CC: adjusted OR = 1.01, 95% CI = 0.77–1.33, P = 0.924; TT vs. CC/CT: adjusted OR = 1.41, 95% CI = 0.79–2.54, P = 0.245). Moreover, stratified analysis revealed no significant associations.

Conclusion

This study provided no evidence of an association between the lnc-AMFR-1:1 rs4784659 C > T polymorphism and the risk of neuroblastoma. These findings warrant validation in larger and more diverse populations.